Acadia Pharmaceuticals | ACAD - Current Assets


Acadia Pharmaceuticals reported $1.06B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cara Therapeutics USD 38.44M 4.69M Sep/2025
Corcept Therapeutics USD 485.46M 55.67M Dec/2025
Cytokinetics USD 916.97M 60.37M Dec/2025
Eisai JPY 840.88B 50.18B Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Moderna USD 6.54B 54M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Prothena USD 315.19M 24.78M Dec/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025